Bukwang Pharmaceutical Co., Ltd. (003000.KS)
003000.KS Stock Price Chart
Explore Bukwang Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze 003000.KS price movements and trends.
003000.KS Company Profile
Discover essential business fundamentals and corporate details for Bukwang Pharmaceutical Co., Ltd. (003000.KS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
29 Sept 2005
Employees
554.00
Website
https://www.bukwang.co.krCEO
Jae-Young Lee
Description
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
003000.KS Financial Timeline
Browse a chronological timeline of Bukwang Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 20 Apr 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 20 Oct 2025
Earnings released on 23 Jul 2025
EPS came in at ₩93.89 , while revenue for the quarter reached ₩42.58B .
Earnings released on 22 Apr 2025
EPS came in at -₩1.62 , while revenue for the quarter reached ₩47.81B .
Earnings released on 7 Feb 2025
EPS came in at ₩26.99 , while revenue for the quarter reached ₩46.18B .
Earnings released on 22 Oct 2024
EPS came in at ₩2.00 , while revenue for the quarter reached ₩42.60B .
Earnings released on 25 Jul 2024
EPS came in at -₩50.53 , while revenue for the quarter reached ₩36.83B .
Earnings released on 23 Apr 2024
EPS came in at -₩37.37 , while revenue for the quarter reached ₩34.39B .
Earnings released on 29 Feb 2024
EPS came in at -₩157.72 , while revenue for the quarter reached ₩25.02B .
Earnings released on 14 Nov 2023
EPS came in at -₩235.00 , while revenue for the quarter reached ₩20.25B .
Earnings released on 10 Aug 2023
EPS came in at ₩7.00 , while revenue for the quarter reached ₩43.42B .
Earnings released on 15 May 2023
EPS came in at -₩84.56 , while revenue for the quarter reached ₩37.23B .
Earnings released on 31 Jan 2023
EPS came in at ₩11.11 , while revenue for the quarter reached ₩61.48B .
Earnings released on 11 Nov 2022
EPS came in at -₩10.00 , while revenue for the quarter reached ₩49.64B .
Earnings released on 16 Aug 2022
EPS came in at -₩6.02 , while revenue for the quarter reached ₩42.87B .
Earnings released on 13 May 2022
EPS came in at -₩31.57 , while revenue for the quarter reached ₩36.91B .
Earnings released on 17 Mar 2022
EPS came in at ₩28.45 , while revenue for the quarter reached ₩53.94B .
Dividend declared on 29 Dec 2021
A dividend of ₩100.00 per share was announced, adjusted to ₩100.00. The dividend was paid on 11 Apr 2022.
Earnings released on 12 Nov 2021
EPS came in at ₩10.00 , while revenue for the quarter reached ₩47.82B .
Earnings released on 13 Aug 2021
EPS came in at -₩3.75 , while revenue for the quarter reached ₩43.86B .
Earnings released on 14 May 2021
EPS came in at -₩45.98 , while revenue for the quarter reached ₩36.86B .
Earnings released on 11 Mar 2021
EPS came in at -₩18.03 , while revenue for the quarter reached ₩49.47B , missing expectations by -6.14%.
Dividend declared on 29 Dec 2020
A dividend of ₩90.91 per share was announced, adjusted to ₩90.91. The dividend was paid on 9 Apr 2021.
Stock split effective on 29 Dec 2020
Shares were split 11 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2020
EPS came in at -₩90.91 , while revenue for the quarter reached ₩40.35B , missing expectations by -6.38%.
003000.KS Stock Performance
Access detailed 003000.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.